The shingles vaccine has been shown to potentially protect older adults from developing dementia, according to recent studies. Research published in the Annals of Internal Medicine indicates that among nursing home residents aged 66 and older, those who received the shingles vaccine within a year of admission had a 5.8% lower risk of dementia over four years, based on data from over 509,000 patients. Additional international studies have reported similar findings, with reduced dementia risk linked to shingles vaccination in populations across Wales, Australia, and Canada. The varicella-zoster virus, which causes shingles, can lead to inflammation in the brain and the accumulation of harmful proteins associated with Alzheimer’s disease. Experts suggest that the vaccine may enhance overall immune function, which could further reduce the risk of cognitive decline.
Why It Matters
This research highlights a significant public health benefit of the shingles vaccine, particularly for older adults, a demographic already at increased risk for both shingles and dementia. Historical data shows that more than 99% of Americans born before 1980 have had chickenpox, leaving them susceptible to shingles later in life. Approximately 1 million cases of shingles occur annually in the U.S., and previous studies have established a correlation between shingles infections and heightened dementia risk. The findings could influence vaccination recommendations and healthcare strategies aimed at improving brain health among aging populations.
Want More Context? 🔎
